Court rules against Teva in generic harm case; FDA approves new use of Stelera; EC gives nod to Gilead's Tybost;

@FiercePharma: Top story yesterday online: If reps can't get in doctors' front doors, try alternate routes. Item | Follow @FiercePharma

@EricPFierce: Judge smokes jury's $1.7 million verdict against Takeda for not properly warning on Actos dangers. Article | Follow @EricPFierce

> The European Commission has approved use of Gilead Sciences' ($GILD) Tybost, a pharmacokinetic enhancer that boosts blood levels of certain HIV medicines. Release

> A federal appeals court in California has sided with plaintiffs against Teva Pharmaceutical Industries ($TEVA) in more cases trying to hold generic drugmakers accountable for alleged harm from ingredients that the reference drug requires. Story

> Florida Republican Representative Bill Young is asking FDA Commissioner Margaret Hamburg to evaluate whether some actions on drug pricing and gray market sales might help reduce drug shortages. Report

> The FDA has approved Janssen Biotech's Anti-IL-12/23 treatment Stelara (ustekinumab), alone or in combination with methotrexate, for the treatment of adult patients with active psoriatic arthritis. Release

Medical Device News

@FierceMedDev: axes jobs after FDA warns over pump. News | Follow @FierceMedDev

@MarkHFierce: KKR sealed the deal to buy Panasonic's healthcare business for $1.67B. Higher than expected. Press release | Follow @MarkHFierce

@MichaelGFierce: Laser-sensitive surface enables IV-drug identification for safer delivery. ICYMI from FierceDrugDelivery | Follow @MichaelGFierce

> Medtronic wins FDA nod to roll out auto-stop insulin device. Report

> Singulex grabs $55M in debt, equity for global in vitro diagnostics push. Article

Biotech News

@FierceBiotech: Popular yesterday: In another stinging setback, Eli Lilly's ramucirumab fails PhIII breast cancer study. Article | Follow @FierceBiotech

@JohnCFierce: ICYMI: Nektar Therapeutics shares crash on PhII pain drug trial flop. Story | Follow @JohnCFierce

@DamianFierce: After a so-so IPO, Regado is axing 15% of its employees, mostly in R&D. Article | Follow @DamianFierce

> ArQule rises on renewed hope for twice-damned tivantinib. More

> Third Rock's path to success lined with patience, rigor and T-shirts. Story

> Inotek snags $21M for PhII glaucoma drops. Item

> Yale biotech spinout launches with $18M and a new approach to cancer. Report

And Finally... GlaxoSmithKline ($GSK) will add 20 jobs to a plant in Cork, Ireland, as part of expansion there. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.